I join >1900 members of US National Academies of Science, Engineering, and Medicine signing this letter, as individuals, decrying the present thoughtless assault on science, which is against our national interests. docs.google.com/document/d/1... Our health, wealth, and security depend on science.
A great opportunity to test a new technology! 👏Ultima Genomics for prioritizing and supporting grants at risk for budget cuts.
ABRF EB meeting ongoing and we are talking about the new strategic plan. Can't wait to share it with the membership. #ABRF2025 #ABRF #StrategicPlan
A reporting page from @seandavis for affected US Government Biomedical Data resources. Sunday not a good day. stats.uptimerobot.com/Zrqh8AhvKn
By this point, NIH lawyers were grim in their prognosis. If the agency moved forward with slashing indirect cost rates, they explained, individual staff members could be prosecuted for failing to comply with a congressional directive. On February 10, Sean R. Keveney, HHS’s acting general counsel, sent a memo to Flick Melanson that included a directive in bold, italicized font: All payments that are due under existing grants and contracts should be un-paused immediately. Two days later, Lauer, the extramural-research director, issued a memo authorizing his colleagues to resume issuing awards—what should have been the agency’s final all-clear to return to normalcy. Even then, the staff remained divided on how to proceed. Some institutes immediately began sending out awards: Lauer’s email spurred one institute, a current official told me, to process 100 grants in a single afternoon.
The leadership and staff at the NIH institute who processed 100 grants in an afternoon are heroes. www.theatlantic.com/health/archi...
By @katherinejwu.com
"The NIH... supported 99 percent of the drugs approved in the U.S. from 2010 to 2019. The agency has had a hand in “nearly all of our major medical breakthroughs over the past several decades,”
The NIH is in a struggle for its (and our) lives. This is existential to America:
💯. I’m looking for the best tools for my small institute to “tinker” with new methods without breaking their budgets. A midsize sequencer is the best bet for sure!
Amen to this! I want to choose based upon the technology’s merits. I already know what niches I need to fill at my institute.
Genomics techniques are so close to being full on meals.
